Pharma and Biotech Opportunities in Emerging Markets

Day One - Sunday, 27 April 2008
09.00	Opening remarks
09.10	Global Pharma Perspective Government Support Problems in the West Opportunities in Developing Markets Drug Development Partnership R&D and Clinical Development Healthcare Systems Guy Fish,  Vice President, Fletcher Spaght Inc./Spaght Ventures
09.40	Key Note: Global Biotech State of the Union G. Steven Burrill, CEO, Burrill & Company
10.20	Break
10.40	Pharmaceutical and Biotechnology Landscape of BRIC countries Development Trends Drivers Current Developments Future prospects Dr. S.M. Chandrashekhar, Medical Director,  Aviccenna Pharma Development
11.20	Strategies for Emerging Bio/Pharm Markets  The Innovation Gap Opportunities for Emerging Economies Implementing globally acceptable Regulatory Requirements Increased Competition – Differentiating the Offering Speed-to-Market and Value for Money Adapting to Market Dynamics Strategic Innovation Generalised vs. Personalised Medicine Stephen McDonald, Healthcare and Intellectual Property Consultant, Research Partners Dubai
12.00	Panel Discussion: Compare and Contrast the Development in Developing Markets India UAE China Brazil Russia Egypt Jordan
12.40	Lunch break
14.00	International Expectations for Standards of Marketing and Sales Sally Jeffery, Director Advisory Services, PriceWaterhouseCoopers
14.40	Changing Needs of R&D Lower costs of outsourcing Shared risks/returns Increasing exit values Program management Translational research Dr. Wolfgang Greb, Founder/CEO, Focus Clinical Drug Development GmbH
15.20	Break
15.40	Operational Strategies: Investing in People Management HR finding the Best people Personnel Qualifications Cultural differences Kazem Behbehani, Envoy, World Health Organization
16.20	Challenges Facing Start-ups Stages of Development of Small Biotech Companies Major Criteria for Investment Challenges Success and Risk Factors Examples of Success and Failures Lynn Katsoulis, RAC Associate Director Drug Development, Associate Managing Director Cato Research South Africa
17.00	Close
Day Two - Monday, 28 April 2008
09.30	The Opportunity not Acquired in the UAE What are the incentives to establish a Bio/Pharm company in UAE? Regional Economies Government Authorities and Policies Free Zones/Bio-clusters Yahya Al Ansari, Director of Community Affairs, Zayed University
10.10	Dubai: Between Boston and Bangalore UAE and GCC perspective: Environmentally Conscious states, Limited Natural resources-needs to be conserved, Biotech Clusters offer facility, Regulatory Framework maintain advanced regulatory standards.  Considerations for setting Biotech facility in the UAE: Land Cost, Power supply, Cost of skilled manpower, Intellectual property. Why setting up Biotech facility in the UAE: Quality Image, Quality Culture, Access to Eastern and Western markets, MENA market potential, Government / Biotech cluster support.      UAE and GCC perspective: Environmentally Conscious states, Limited Natural resources-needs to be conserved, Biotech Clusters offer facility, Regulatory Framework maintain advanced regulatory standards.  Mr. Debayan Ghosh, President, Epygen Biotech
10.50	The GCC and the Potential for Clinical Research  Overview of Health Care Systems Main Health Problems in the GCC Clinical Research Infrastructure Good Clinical Practice Implementation International Expertise Common Problem and Pitfalls Maha Al-Farhan, Managing Director, Middle East CRO, Chair of the GCC Chapter of the Association of Clinical Research Professional
11.30	Break
11.50	International new product development Success Rate, Future Trends Research Strategy to Acquire Patent Protection Measures for Increasing R&D Activities in Jordan and the Region Case Studies of Regional Attempts in this Interesting Area Biotech Industry Worldwide The Need to Deliver Peptides and Proteins What do We Have, and We Would Like to do? Dr. Ahmad Al Ghazawi, Founder, President and CEO, Triumpharma
12.30	Bioethical Issues and Business Risk Bioethics & Business Compelling Issues: Pharmacovigilence, CRO’s, Shari’a and Global Standards Colleen Lyons, MBe, Principal, The Lyons Trust
13.10	Lunch Break
14.30	Increasing Contribution to Global Drug Development by South East Asia Countries and Creating a Strong Biomedical Research Hub in Asia- The Singapore Experience Ellick Wong, Professor, National University Singapore
15.10	Establishing your Presence in the Middle East Government Support Drug Development Leadership Partnership R&D and Clinical Development Ben Figgis, Marketing Manager, Qatar Science & Technology Park
15.50	Break
16.10	Opportunities for Pharma in a 2020 World Current trends in pharmaceuticals and biotech and the likely environment in 2020 The specific challenges in R&D, supply chain, sales and marketing and regulatory Sustainability and CSR Actions that pharma and biotech need to take to address the opportunities in a changing world The opportunities that this presents for the Middle East region Jo Pisani, Assistant Director Valuation and Strategy of Pharmaceuticals, PricewaterhouseCoopers LLP
16.50	Roundtable Discussion
17.30	Close
Invited Faculty
Jo Pisani, Assistant Director, Valuation and Strategy of Pharmaceuticals, PricewaterhouseCoopers LLP Lynn Katsoulis, RAC Associate Director Drug Development, Associate Managing Director Cato Research South Africa G. Steven Burrill, CEO, Burrill & CO Sally Jeffery, Director Advisory Services, PriceWaterhouseCoopers Guy Fish, Vice President, Fletcher Spaght Inc./Spaght Ventures Dr. S.M. Chandrashekhar, Medical Director, Aviccenna Pharma Development Dr. Wolfgang Greb, Founder/CEO, Focus Clinical Drug Development GmbH Ellick Wong, Professor, National University Singapore Ben Figgis, Marketing Manager, Qatar Science & Technology Park Yahya Al Ansari, Director of Community Affairs, Zayed University Maha Al-Farhan, Managing Director, Middle East CRO, Chair of the GCC Chapter of the Association of Clinical Research Professional Kazem Behbehani, Envoy, WHO Dr. Ahmad Al Ghazawi, Founder, President and CEO, Triumpharma, LLC Dr. B.R. Shetty, CEO, Neopharma Colleen Lyons, MBe, Principal, The Lyons Trust Stephen McDonald, Healthcare and Intellectual Property Consultant, Research Partners Dubai Debayan Ghosh, President, Epygen Biotech
Back to Conference Programmes